Pfizer announced that the recommendation is based on data from the Phase III clinical trial, PALOMA-3, in which Ibrance delayed disease progression by 6.6 months, compared to fulvestrant alone.
On the announcement of the news, the drug combination will be available on the NHS immediately, for use in those who have already had earlier rounds hormone therapy for their advanced disease.
Pfizer also revealed an estimation that as many as 3,200 women in England living with advanced HR+, HER2- breast cancer will now be eligible for the treatment…
